Dynavax Appoints Bain Capital’s Andrew Hack, to the Board of Directors

Dynavax Technologies Andrew Hack
Dynavax Technologies Andrew Hack

Dynavax Technologies Corporation, a biopharmecuitical company that focuses on commercializing novel vaccines, today announced Andrew A. F. Hack, M.D., Ph.D., a Managing Director at Bain Capital Life Sciences, has been appointed to Dynavax’s Board of Directors. The appointment follows an investment by Bain Capital Life Sciences in Dynavax’s recently completed public offering.

Dynavax is a biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers, develops and commercializes novel vaccines.

READ MORE: Toast Announces $400M in Series F Funding

The Company launched its first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], in February 201...

Login In


Register now for free access

Notify of
Inline Feedbacks
View all comments